Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian villagers.
Hill, Philip C;
Akisanya, Abiodun;
Sankareh, Kawsu;
Cheung, Yin Bun;
Saaka, Mark;
Lahai, George;
Greenwood, Brian M;
Adegbola, Richard A;
(2006)
Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian villagers.
Clinical infectious diseases, 43 (6).
pp. 673-679.
ISSN 1058-4838
DOI: https://doi.org/10.1086/506941
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
BACKGROUND: To prepare for the introduction of a pneumococcal conjugate vaccine of restricted valency, we studied the nasopharyngeal carriage of Streptococcus pneumoniae in Gambian villagers. METHODS: A cross-sectional survey was conducted in 21 villages after a census. We recorded demographic characteristics, information on medical history, and data on possible risk factors for carriage from subjects. We collected a nasopharyngeal swab specimen from each subject for isolation and serotyping of S. pneumoniae and for antibiotic susceptibility testing. RESULTS: The prevalence of S. pneumoniae carriage among 2872 villagers was 72%. It was highest among infants (i.e., children aged <1 year; 97%); the rate was 93% among babies aged <1 month and decreased with increasing age (P<.001). Prevalence of carriage was linked to proximity to another village. Sixty-three percent of isolates recovered from children aged <5 years were covered by the 7-valent vaccine or were of a vaccine-related serotype, compared with 43% of isolates overall. Forty-three isolates (14.3%) tested were initially penicillin resistant; none had high-level resistance, and 4 had intermediate resistance. The rates of resistance to other antibiotics were as follows: trimethoprim-sulfamethoxazole, 39%; tetracycline, 32.3%; chloramphenicol, 6.3%; cefotaxime, 0.3%; and erythromycin, 0%. The rates were highest for isolates of vaccine serotypes. CONCLUSIONS: Pneumococcal carriage rates among Gambian villagers are very high. A pneumococcal conjugate vaccine of restricted valency should reduce the pool of antibiotic-resistant pneumococci. The large reservoir of pneumococci of nonvaccine serotypes will require close monitoring when the vaccine is introduced.